Cipla Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Cipla heeft de winst zien groeien met een gemiddeld jaarlijks percentage van 14.9%, terwijl de Pharmaceuticals-industrie de winst zag groeien met 14.9% per jaar. De inkomsten zijn gegroeid met een gemiddeld jaarlijks percentage van 7.1%. Het rendement op eigen vermogen van Cipla is 9.7%, en het heeft een nettomarge van 12%.
Belangrijke informatie
14.87%
Groei van de winst
14.84%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 17.49% |
| Inkomstengroei | 7.14% |
| Rendement op eigen vermogen | 9.72% |
| Nettomarge | 12.01% |
| Laatste winstupdate | 30 Jun 2026 |
Recente prestatie-updates uit het verleden
Recent updates
Analyse-artikel • Jul 26
Cipla Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
As you might know, Cipla Limited ( NSE:CIPLA ) recently reported its first-quarter numbers. Revenues were in line with...
Narratiefupdate • Jul 24
CIPLA: Fair Outlook As Respiratory Diagnostics And Patent Settlement Shape Future Prospects
Analysts have lifted their fair value estimate for Cipla from ₹1,456.73 to ₹1,499.89, citing updated assumptions for revenue growth at 12.04%, profit margin at 16.15%, and a revised future P/E of 27.08x as key drivers of the new price target. What’s in the News for Cipla Cipla shareholders approved the appointment of M/s B S R & Co. LLP as statutory auditors for a five year term at the 90th AGM held on June 25, 2026, following the completion of the second term of M/s Walker Chandiok & Co. LLP as auditors.Narratiefupdate • Jun 22
CIPLA: Fair Outlook As Respiratory Diagnostics And US Generics Pipeline Evolve
Analysts have marginally reduced their fair value estimate for Cipla, trimming the price target from about ₹1,460 to roughly ₹1,457 as they fine-tune assumptions on long term profit margins and forward P/E multiples, while keeping core growth expectations broadly unchanged. What’s in the News for Cipla Cipla launched Ciposcillo, an advanced oscillometer for early detection of respiratory diseases such as COPD and asthma, built on US FDA cleared technology and approved by India’s CDSCO.Narratiefupdate • Jun 05
CIPLA: Fair Outlook As New CEO And Respiratory Portfolio Changes Take Shape
Analysts have raised their price target on Cipla by about ₹30 to ₹1,459.57, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple, alongside a marginally higher discount rate. What's in the News Cipla launched Ciposcillo, an advanced oscillometer for early detection of respiratory diseases like COPD and asthma.Analyse-artikel • May 16
Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...Narratiefupdate • Apr 27
CIPLA: New CEO, US Respiratory Launch And Biologics Venture Will Steady Outlook
Analysts now place Cipla's fair value at ₹1,429.83, a small move from ₹1,427.58. This reflects refreshed assumptions around revenue growth, profit margin and future P/E expectations.Narratiefupdate • Apr 12
CIPLA: New CEO And Biologics Venture Will Support Stronger Outlook
Cipla's analyst fair value estimate has been adjusted slightly from about ₹1,436.58 to ₹1,427.58, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations according to analysts. What's in the News Cipla plans a board meeting on May 13, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for the year, if any (company filing).Narratiefupdate • Mar 27
CIPLA: New CEO And Biologics Venture Will Support Stronger Long Term Outlook
Analysts have trimmed Cipla's implied fair value price target slightly from ₹1,446.31 to ₹1,436.58, reflecting updated views on its revenue growth, profit margin outlook, and future P/E assumptions. What's in the News A board meeting is scheduled for 19 Mar 2026 to consider appointing P R Ramesh, Lead Independent Director, as Vice Chairman, and to take up the planned exit of Independent Director Robert Stewart after completion of his current term, along with other matters (Key Developments).Narratiefupdate • Mar 13
CIPLA: Pfizer Alliance And CEO Transition Will Shape Steady Forward Outlook
Analysts have kept their Cipla price target unchanged at ₹1,446.31, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E in their models. What's in the News Cipla has agreed to a 60:40 joint venture with Kemwell Biopharma in India to develop, obtain licenses for, manufacture, commercialise, import and export biologic products, with scope to license or outsource these activities (company announcement).Narratiefupdate • Feb 27
CIPLA: Pfizer Tie-Up And Leadership Shift Will Shape Balanced Outlook
Analysts have trimmed their price target on Cipla by about ₹10 to reflect slightly softer assumptions around long term revenue growth and profit margins, while keeping the P/E framework broadly unchanged. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, including Corex Dx, Corex LS, Dolonex, Neksium and Dalacin C, while Pfizer continues to manufacture and supply these medicines (Key Developments).Narratiefupdate • Feb 13
CIPLA: Pfizer Partnership And Upcoming Results Will Guide Balanced Future Expectations
Analysts have trimmed their price target for Cipla slightly to ₹1,456 from about ₹1,459, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E that are broadly in line with prior views. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, covering Corex Dx and Corex LS cough syrups, Dolonex (NSAID), Neksium (PPI) and Dalacin C (oral antibiotic).Narratiefupdate • Jan 30
CIPLA: Pfizer Alliance And Upcoming Results Will Shape Measured Future Upside Potential
Analysts have revised their fair value estimate for Cipla to ₹1,458.53, down from ₹1,657.58, citing updated assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Cipla has scheduled a board meeting on Jan 23, 2026, at 11:00 Indian Standard Time to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Analyse-artikel • Jan 28
Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...Analyse-artikel • Jan 17
The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet
With a price-to-earnings (or "P/E") ratio of 20.7x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...Narratiefupdate • Jan 16
CIPLA: Pfizer Partnership And Leadership Transition Will Support Future Upside Potential
Analysts have slightly reduced their fair value estimate for Cipla to ₹1,658 from ₹1,677, citing updated assumptions that combine modestly higher revenue growth expectations with some pressure on profit margins and a marginally adjusted future P/E multiple. What's in the News A board meeting is scheduled on January 23, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Analyse-artikel • Dec 29
We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyse-artikel • Nov 20
Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyse-artikel • Nov 02
Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report
Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...Analyse-artikel • Sep 24
Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 22.9x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...Analyse-artikel • Sep 06
Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Narratiefupdate • Sep 04
Emerging Markets And Chronic Therapies Will Open New Horizons
With consensus forecasts for both revenue growth (8.4% p.a.) and net profit margin (15.92%) remaining steady, Cipla's Analyst Price Target was left unchanged at ₹1677. What's in the News Cipla is significantly expanding its US manufacturing capacity with an 83,000-square-foot addition at its Fall River, Massachusetts facility, focusing on complex respiratory products, and will utilize advanced technology to enhance production and efficiency.
Nieuw narratief • Nov 10
Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions
Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.Opbrengsten en kosten
Opbrengsten en kosten
Hoe Cipla geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 26 | 280,678 | 33,707 | 69,601 | 0 |
| 31 Mar 26 | 278,278 | 38,792 | 67,750 | 0 |
| 31 Dec 25 | 279,672 | 45,464 | 64,591 | 0 |
| 30 Sep 25 | 279,658 | 54,411 | 63,317 | 0 |
| 30 Jun 25 | 274,796 | 53,925 | 62,248 | 0 |
| 31 Mar 25 | 272,674 | 52,725 | 61,067 | 0 |
| 31 Dec 24 | 267,201 | 49,897 | 58,640 | 0 |
| 30 Sep 24 | 262,642 | 44,751 | 57,345 | 0 |
| 30 Jun 24 | 258,922 | 43,035 | 56,178 | 0 |
| 31 Mar 24 | 255,367 | 41,216 | 54,901 | 0 |
| 31 Dec 23 | 251,163 | 37,082 | 53,757 | 0 |
| 30 Sep 23 | 243,407 | 34,532 | 52,563 | 0 |
| 30 Jun 23 | 235,108 | 31,112 | 51,260 | 0 |
| 31 Mar 23 | 225,593 | 28,019 | 50,151 | 0 |
| 31 Dec 22 | 222,187 | 26,383 | 48,947 | 0 |
| 30 Sep 22 | 218,874 | 25,660 | 48,184 | 0 |
| 30 Jun 22 | 216,105 | 24,884 | 35,984 | 0 |
| 31 Mar 22 | 217,078 | 25,168 | 46,669 | 0 |
| 31 Dec 21 | 210,718 | 25,681 | 43,285 | 0 |
| 30 Sep 21 | 207,616 | 25,876 | 43,004 | 0 |
| 30 Jun 21 | 202,801 | 25,417 | 42,435 | 0 |
| 31 Mar 21 | 191,205 | 24,049 | 41,281 | 0 |
| 31 Dec 20 | 188,779 | 22,374 | 40,432 | 0 |
| 30 Sep 20 | 180,802 | 18,403 | 39,444 | 0 |
| 30 Jun 20 | 174,377 | 16,462 | 38,851 | 0 |
| 31 Mar 20 | 170,805 | 15,465 | 38,694 | 0 |
| 31 Dec 19 | 171,206 | 16,678 | 38,608 | 0 |
| 30 Sep 19 | 167,572 | 16,489 | 38,331 | 0 |
| 30 Jun 19 | 163,733 | 15,546 | 37,837 | 0 |
| 31 Mar 19 | 163,232 | 15,277 | 37,415 | 0 |
| 31 Dec 18 | 155,224 | 13,391 | 35,683 | 0 |
| 30 Sep 18 | 154,287 | 14,074 | 35,078 | 0 |
| 30 Jun 18 | 154,992 | 14,530 | 34,564 | 0 |
| 31 Mar 18 | 151,053 | 14,105 | 34,151 | 0 |
| 31 Dec 17 | 147,618 | 11,701 | 32,973 | 0 |
| 30 Sep 17 | 144,951 | 11,444 | 32,730 | 0 |
| 30 Jun 17 | 141,637 | 10,762 | 32,875 | 0 |
| 31 Mar 17 | 143,340 | 10,064 | 33,011 | 0 |
| 31 Dec 16 | 142,509 | 11,213 | 31,554 | 0 |
| 30 Sep 16 | 137,547 | 10,071 | 31,012 | 0 |
| 30 Jun 16 | 134,335 | 12,219 | 30,089 | 0 |
| 31 Mar 16 | 135,480 | 13,600 | 29,258 | 0 |
| 31 Dec 15 | 135,044 | 16,847 | 39,028 | 1,120 |
| 30 Sep 15 | 131,633 | 16,694 | 38,220 | 1,120 |
Kwaliteitswinsten: CIPLA heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (12%) CIPLA } zijn lager dan vorig jaar (19.6%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van CIPLA is de afgelopen 5 jaar met 14.9% per jaar gegroeid.
Versnelling van de groei: De winstgroei CIPLA is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.
Winst versus industrie: CIPLA had het afgelopen jaar een negatieve winstgroei ( -37.5% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Pharmaceuticals ( 16.6% ).
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 9.7% ) van CIPLA wordt als laag beschouwd.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/03 15:16 |
| Aandelenkoers aan het einde van de dag | 2026/08/03 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Cipla Limited wordt gevolgd door 57 analisten. 36 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |